KDM1A and cancer: Further study showed that 65 and 66 showed better anticancer activity against MDA-MBA-231, THP-1, and MV4-11 cells without significant toxicity to non-cancer AHH-1 cells compared with epigenetic drug UNC0638, which suggested that the LSD1 antagonistic activity of LSD1/G9a inhibitors endorsed with anticancer activity (Menna et al., 2022).